Literature DB >> 1870213

Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4.

J A Hoxie1, L F Brass, C H Pletcher, B S Haggarty, B H Hahn.   

Abstract

Naturally occurring isolates of human immunodeficiency virus (HIV) have been described which are deficient in their ability to fuse with and kill CD4+ target cells. Although the molecular basis for their attenuation has not yet been defined, several lines of evidence point toward the viral envelope gene as a key determinant of viral pathogenicity. In the present article, we report the biological characterization of two highly cytopathic variants derived by repeated cell-free passage of an attenuated isolate of HIV type 2 (HIV-2), termed HIV-2/ST. Unlike the parental virus, the cytopathic variants were found to infect Sup-T1 cells with great efficiency and to induce both cell fusion and profound killing in these cultures. To determine whether changes in the viral envelope gene were responsible for the observed phenotypic differences, we examined the CD4 binding affinity of these viruses using a novel assay designed to quantitate the binding of fluoresceinated CD4 to viral envelope in its native configuration on the cell surface. The results demonstrated that the affinity of parental HIV-2/ST envelope for CD4 was 2 orders of magnitude reduced, while the cytopathic variants exhibited a high CD4 binding affinity, comparable to that of cytopathic HIV-1 and HIV-2 isolates. From these data, we conclude that the cytopathic potential of HIV depends, at least in part, on its receptor-binding affinity. In addition, our study documents strong selection pressures for viruses with increased CD4 affinity during propagation in immortalized T-cell lines, thus emphasizing the need to study HIV envelope biology in natural target cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1870213      PMCID: PMC248977     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Infection of T4 lymphocytes by HTLV-III does not require expression of the OKT4 epitope.

Authors:  J A Hoxie; L E Flaherty; B S Haggarty; J L Rackowski
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

2.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

3.  Identification of the residues in human CD4 critical for the binding of HIV.

Authors:  J Arthos; K C Deen; M A Chaikin; J A Fornwald; G Sathe; Q J Sattentau; P R Clapham; R A Weiss; J S McDougal; C Pietropaolo
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

4.  Replicative and cytopathic characteristics of HIV-2 and severity of infection.

Authors:  J Albert; B Böttiger; G Biberfeld; E M Fenyö
Journal:  Lancet       Date:  1989-04-15       Impact factor: 79.321

5.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.

Authors:  A Cordonnier; L Montagnier; M Emerman
Journal:  Nature       Date:  1989-08-17       Impact factor: 49.962

6.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120.

Authors:  R L Willey; E K Ross; A J Buckler-White; T S Theodore; M A Martin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Authors:  R A Byrn; I Sekigawa; S M Chamow; J S Johnson; T J Gregory; D J Capon; J E Groopman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

9.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.

Authors:  E M Fenyö; L Morfeldt-Månson; F Chiodi; B Lind; A von Gegerfelt; J Albert; E Olausson; B Asjö
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

10.  Characterization of a noncytopathic HIV-2 strain with unusual effects on CD4 expression.

Authors:  L A Evans; J Moreau; K Odehouri; H Legg; A Barboza; C Cheng-Mayer; J A Levy
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

View more
  17 in total

1.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

2.  Fusogenic variants of a noncytopathic paramyxovirus.

Authors:  Shaguna Seth; Ioanna Skountzou; Kim M Gernert; Richard W Compans
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

3.  The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

Authors:  J D Reeves; T F Schulz
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.

Authors:  M J Mulligan; G V Yamshchikov; G D Ritter; F Gao; M J Jin; C D Nail; C P Spies; B H Hahn; R W Compans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity.

Authors:  B A Brody; S S Rhee; E Hunter
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner.

Authors:  C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.

Authors:  Q J Sattentau; J P Moore; F Vignaux; F Traincard; P Poignard
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.